title: Iliopectineal bursitis associated with rapid destruction of a rheumatoid hip joint.
authors: Department of Orthopedic Surgery, Tokyo Metropolitan Ohtsuka Hospital, Minami-ohtsuka, Toshima-ku, Tokyo, Japan.
authors: Toshiyuki
authors: T
authors: Tateiwa
authors: Kotaro
authors: K
authors: Shinmura
authors: Meisyu
authors: M
authors: Ko
authors: Junya
authors: J
authors: Mibe
authors: Kengo
authors: K
authors: Yamamoto
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D019644:Arthroplasty, Replacement, Hip / Q000379:methods*; D001707:Biopsy, Needle; D002062:Bursitis / Q000150:complications / Q000175:diagnosis*; D005260:Female; D005500:Follow-Up Studies; D006620:Hip Fractures / Q000000981:diagnostic imaging / Q000209:etiology / Q000473:pathology* / Q000601:surgery*; D006801:Humans; D007150:Immunohistochemistry; D000069285:Infliximab; D008279:Magnetic Resonance Imaging; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D020127:Recovery of Function; D012263:Ribonucleosides / Q000009:adverse effects / Q000627:therapeutic use; D018570:Risk Assessment; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D012263:Ribonucleosides; C010052:mizoribine; D011239:Prednisolone; D000069285:Infliximab